NCT04477759 - Dose-Escalated Hypofractionated Adaptive Radiotherapy for Head and Neck Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 26, 2021

Primary Completion Date

April 8, 2024

Study Completion Date

April 14, 2025

Conditions

Head and Neck Neoplasm

Interventions

RADIATION

50 Gy Radiation Therapy

Ionizing radiation

RADIATION

55 Gy Radiation Therapy

Ionizing radiation

RADIATION

60 Gy Radiation Therapy

Ionizing radiation

DRUG

Concurrent Atezolizumab

Atezolizumab (1,680 mg) will be given to all subjects by intravenous injection every 4 weeks following the initiation of radiation treatment up to 1 year from radiation fraction 1.

DRUG

Adjuvant Atezolizumab

Atezolizumab (1,680 mg) will be given to all subjects by intravenous injection every 28 days following the initiation of radiation treatment up to 1 year.

Trial Locations (1)

53226

Froedtert & Medical College of Wisconsin, Milwaukee